Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) shares were up 4.4% during mid-day trading on Monday. The company traded as high as $23.75 and last traded at $22.54. Approximately 35,776 shares were traded during mid-day trading, a decline of 92% from the average session volume of 433,881 shares. The stock had previously closed at $21.60.
Analysts Set New Price Targets
Several equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a research note on Tuesday, July 21st. Guggenheim started coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Friday, November 6th. They issued a "buy" rating and a $59.00 price target for the company. Wedbush reiterated an "outperform" rating and issued a $40.00 price objective on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, September 29th. TD Cowen upgraded shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research note on Monday, August 24th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, September 14th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Damora Therapeutics, Inc. Common Stock presently has a consensus rating of "Buy" and a consensus target price of $46.38.
Read Our Latest Research Report on DMRA
Damora Therapeutics, Inc. Common Stock Trading Up 4.1%
The business's fifty day moving average is $22.19 and its 200 day moving average is $25.61. The firm has a market capitalization of $1.39 billion, a P/E ratio of -15.95 and a beta of 1.52.
Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.12. As a group, sell-side analysts predict that Damora Therapeutics, Inc. Common Stock will post -2.09 earnings per share for the current fiscal year.
Insider Activity
In related news, CEO Jennifer Jarrett bought 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction dated Friday, September 25th. The stock was acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the completion of the acquisition, the chief executive officer directly owned 512,500 shares in the company, valued at approximately $10,367,875. This trade represents a 2.50% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.40% of the stock is owned by company insiders.
Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System purchased a new position in Damora Therapeutics, Inc. Common Stock during the 2nd quarter valued at about $260,000. Squarepoint Ops LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the second quarter worth approximately $303,000. Seven Fleet Capital Management LP acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock during the second quarter worth approximately $7,398,000. Finally, Braidwell LP purchased a new position in Damora Therapeutics, Inc. Common Stock during the second quarter valued at approximately $42,146,000. 14.20% of the stock is currently owned by hedge funds and other institutional investors.
Damora Therapeutics, Inc. Common Stock Company Profile
(
Get Free Report)
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Damora Therapeutics, Inc. Common Stock, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Damora Therapeutics, Inc. Common Stock wasn't on the list.
While Damora Therapeutics, Inc. Common Stock currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.